These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
435 related articles for article (PubMed ID: 25337656)
1. Partial blockade of Kv2.1 channel potentiates GLP-1's insulinotropic effects in islets and reduces its dose required for improving glucose tolerance in type 2 diabetic male mice. Sukma Rita R; Dezaki K; Kurashina T; Kakei M; Yada T Endocrinology; 2015 Jan; 156(1):114-23. PubMed ID: 25337656 [TBL] [Abstract][Full Text] [Related]
2. The role of voltage-gated potassium channels Kv2.1 and Kv2.2 in the regulation of insulin and somatostatin release from pancreatic islets. Li XN; Herrington J; Petrov A; Ge L; Eiermann G; Xiong Y; Jensen MV; Hohmeier HE; Newgard CB; Garcia ML; Wagner M; Zhang BB; Thornberry NA; Howard AD; Kaczorowski GJ; Zhou YP J Pharmacol Exp Ther; 2013 Feb; 344(2):407-16. PubMed ID: 23161216 [TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 and islet lipolysis. Sörhede Winzell M; Ahrén B Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711 [TBL] [Abstract][Full Text] [Related]
4. The tarantula toxin GxTx detains K Tilley DC; Angueyra JM; Eum KS; Kim H; Chao LH; Peng AW; Sack JT J Gen Physiol; 2019 Mar; 151(3):292-315. PubMed ID: 30397012 [TBL] [Abstract][Full Text] [Related]
5. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists. Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371 [TBL] [Abstract][Full Text] [Related]
6. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255 [TBL] [Abstract][Full Text] [Related]
7. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370 [TBL] [Abstract][Full Text] [Related]
8. The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice. Fosgerau K; Jessen L; Lind Tolborg J; Østerlund T; Schæffer Larsen K; Rolsted K; Brorson M; Jelsing J; Skovlund Ryge Neerup T Diabetes Obes Metab; 2013 Jan; 15(1):62-71. PubMed ID: 22862961 [TBL] [Abstract][Full Text] [Related]
9. SNAP-25(1-180) enhances insulin secretion by blocking Kv2.1 channels in rat pancreatic islet beta-cells. Zhuang GQ; Wu W; Liu F; Ma JL; Luo YX; Xiao ZX; Liu Y; Wang W; He Y Biochem Biophys Res Commun; 2009 Feb; 379(4):812-6. PubMed ID: 19103161 [TBL] [Abstract][Full Text] [Related]
17. Exendin-4 ameliorates diabetic symptoms through activation of glucokinase. Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M J Diabetes; 2012 Dec; 4(4):369-77. PubMed ID: 22356440 [TBL] [Abstract][Full Text] [Related]
18. Chemoselective tarantula toxins report voltage activation of wild-type ion channels in live cells. Tilley DC; Eum KS; Fletcher-Taylor S; Austin DC; Dupré C; Patrón LA; Garcia RL; Lam K; Yarov-Yarovoy V; Cohen BE; Sack JT Proc Natl Acad Sci U S A; 2014 Nov; 111(44):E4789-96. PubMed ID: 25331865 [TBL] [Abstract][Full Text] [Related]
19. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248 [TBL] [Abstract][Full Text] [Related]
20. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity. Gault VA; Kerr BD; Harriott P; Flatt PR Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]